(Q33438955)

26 July 2017

1 reference

title

Who should benefit from the use of alpha-glucosidase inhibitors? (English)

1 reference

26 July 2017

Ariane Godbout

1

1 reference

26 July 2017

Jean-Louis Chiasson

series ordinal

2

1 reference

26 July 2017

publication date

1 October 2007

1 reference

26 July 2017

published in

Current diabetes report

1 reference

26 July 2017

volume

7

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

333-339

1 reference

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

26 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11892-007-0055-X

Post-challenge hyperglycaemia is associated with premature death and macrovascular complications

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11892-007-0055-X

Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis

21 January 2018

1 reference

12 December 2020

Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients.

1 reference

12 December 2020

Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.

1 reference

12 December 2020

Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy.

1 reference

12 December 2020

An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM

1 reference

12 December 2020

Acarbose in the treatment of elderly patients with type 2 diabetes.

1 reference

12 December 2020

Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients

1 reference

12 December 2020

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

12 December 2020

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance

1 reference

12 December 2020

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

12 December 2020

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study

1 reference

12 December 2020

Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes

1 reference

12 December 2020

Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives.

1 reference

12 December 2020

Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis.

1 reference

12 December 2020

A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes

1 reference

12 December 2020

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

12 December 2020

The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes

1 reference

12 December 2020

Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels.

1 reference

12 December 2020

Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies

1 reference

12 December 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

1 reference

12 December 2020

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

12 December 2020

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

1 reference

12 December 2020

Effect of acarbose in treatment of type II diabetes mellitus: a double-blind, crossover, placebo-controlled trial.

1 reference

12 December 2020

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

12 December 2020

Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients

1 reference

12 December 2020

Post-meal coagulation activation in diabetes mellitus: the effect of acarbose

1 reference

12 December 2020

Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance

1 reference

12 December 2020

Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later.

1 reference

12 December 2020

Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients

1 reference

12 December 2020

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

1 reference

12 December 2020

Acarbose ameliorates atherogenecity of low-density lipoprotein in patients with impaired glucose tolerance

1 reference

12 December 2020

10.1007/S11892-007-0055-X

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1020877540

0 references

1 reference